Psilocybin Therapy: What the Evidence Shows (2026)

Q: Can I legally get psilocybin therapy in Europe today?

For most people, only by joining a clinical trial. Psilocybin is not an approved medicine in the EU, so supervised therapy outside research is not generally lawful. Three countries are exceptions with real limits: Czechia's new framework is legal but not yet delivering treatment, Germany's compassionate use program is tiny and time-limited, and Switzerland's limited medical use route runs through a small number of authorised physicians. Anyone offering psilocybin therapy commercially outside these routes is operating illegally.

Q: Is psilocybin an approved treatment for depression?

Not yet, anywhere in Europe. The evidence in treatment-resistant depression is strong — two Phase 3 trials met their primary endpoints in 2025 and 2026 — but positive trial results are not the same as regulatory approval. A marketing application still has to be filed and reviewed before psilocybin could become an approved medicine.

Q: How strong is the evidence, really?

It varies by condition. Treatment-resistant depression has the strongest evidence, now at Phase 3. Broader major depression is promising but rests on smaller studies, one of which did not beat an active comparator on its main measure. Uses in cancer-related distress and addictions are early. Being honest about these tiers matters more than any single headline.

Q: Is psilocybin dangerous?

Under clinical supervision, serious harms are rare and its physiological toxicity is low. The main safeguards are screening — people with a history of psychosis or bipolar disorder, or significant heart disease, are generally excluded — and the supervised, supported setting. A minority of people, mostly using outside clinical settings, report prolonged psychological difficulties, which is one reason the controlled model exists.

Q: Are the truffle retreats in the Netherlands the same thing?

No. Legal psilocybin truffle retreats operate under a quirk of Dutch law and are not medical treatment, not clinical trials, and not covered here as an evidence-based therapy. This page addresses the clinical and regulatory picture only.

If you are trying to understand what psilocybin therapy can and cannot do — for yourself, for someone close to you, or simply to separate the science from the headlines — this page lays out the evidence as it stands in July 2026. Psilocybin, the compound in so-called magic mushrooms, has been studied as a treatment for depression and several other conditions in supervised clinical settings. The results in one indication are now genuinely strong; in others they are early and easy to overstate. This is a clinical and legal summary only: it does not describe doses, preparation, or what a session feels like, and it is not a guide to obtaining or using psilocybin.

TL;DR Psilocybin is an investigational drug, not an approved medicine in the EU. Its best evidence is in treatment-resistant depression, where Compass Pathways' two Phase 3 trials met their primary endpoints in 2025 and 2026 — the first psilocybin program to reach that milestone. Other uses, from cancer-related distress to alcohol use disorder, look promising but rest on small early studies. Under clinical supervision serious harms are rare, but trials screen carefully for psychosis and bipolar history and for heart disease, and a minority of people report lasting difficulties. In Europe, lawful access is essentially clinical trials plus three national exceptions (Switzerland, Germany, Czechia).

What it is

Psilocybin is a naturally occurring serotonergic psychedelic, converted in the body to psilocin, which acts mainly at the brain's serotonin 2A receptor. In research it is given as a purified or synthetic compound — for example Compass Pathways' synthetic COMP360 — in a single supervised session, or occasionally two, with preparation beforehand and psychological support and integration afterwards. This delivery model, sometimes called psilocybin-assisted therapy, treats the drug as one component of a structured course of care rather than a pill taken at home (Blossom compound overview).

Regulatory status, stated plainly: psilocybin is not an approved medicine anywhere in the European Union. It has no EMA marketing authorisation and no national approval for general medical use. It is investigational — lawful primarily inside authorised clinical trials — with three narrow national exceptions covered below: Switzerland's limited medical use program, Germany's compassionate use program, and the Czech national framework that took legal effect on 1 January 2026. Everywhere else in Europe, supervised psilocybin therapy outside a trial is not a lawful medical treatment.

What the evidence shows

The honest picture is a set of tiers. One indication has crossed into Phase 3 with positive results; the rest are earlier and should be described as such.

Approved and established use: none

There is no established, approved clinical use of psilocybin in Europe. No regulator has authorised it as a medicine, so no indication sits in an "established practice" tier. Everything below is research evidence, however encouraging, and should be read that way.

Treatment-resistant depression — strong clinical-trial evidence

This is where the evidence is strongest. The pivotal early signal came from Compass Pathways' Phase 2b trial of COMP360, a randomised, double-blind study of 233 patients with treatment-resistant depression across ten countries — the largest psilocybin trial published to date — in which a single 25 mg dose produced a statistically significant reduction in depression scores at week three versus a 1 mg comparator, with roughly 30% of the 25 mg group in remission at week three and a smaller durable response persisting to week twelve. It was published in the New England Journal of Medicine in November 2022 (Goodwin et al., NEJM 2022; Compass announcement).

That signal has now been confirmed at Phase 3. Compass's COMP005, the first of two pivotal trials, met its primary endpoint in 2025 (Compass Pathways, COMP005). The second, COMP006, reported a highly statistically significant result at its six-week primary endpoint in February 2026 — a 25 mg dose versus a 1 mg comparator, with a clinically meaningful difference in symptom change (p<0.001) — and in July 2026 Compass released 26-week data confirming a rapid onset and a durable profile in a meaningful share of responders (Psychiatric Times, Phase 3 efficacy; Compass 26-week data). Across both trials the drug has been generally well tolerated, with most adverse events mild or moderate and resolving within a day.

Two caveats keep this in proportion. First, blinding is hard in psychedelic trials — patients usually know whether they received an active dose — which complicates interpretation, a point regulators watch closely. Second, positive pivotal data is not the same as an approval; a marketing application still has to be filed and reviewed.

Major depressive disorder — promising, still maturing

Beyond treatment resistance, psilocybin has been tested in broader major depression. In a widely cited Phase 2 trial, Carhart-Harris and colleagues compared two 25 mg psilocybin sessions with a six-week course of the antidepressant escitalopram in moderate-to-severe depression. The primary depression measure did not differ significantly between groups, but several secondary outcomes and remission rates numerically favoured psilocybin (Carhart-Harris et al., NEJM 2021). It is an encouraging, carefully conducted study — but a single, modestly sized trial that did not separate from an active comparator on its main endpoint sits in the "promising" tier, not the "strong" one. A separate program, Cybin's deuterated psilocin analog CYB003, is now in Phase 3 for major depressive disorder as an adjunct to existing antidepressants, with results awaited (Cybin PARADIGM program).

Distress in life-threatening illness, and addictions — early evidence

Smaller studies have explored psilocybin for anxiety and depression associated with cancer and other serious illness, and for alcohol and tobacco use disorders, with some positive early results. These remain mostly small, single-site or Phase 2 studies, several without the large controlled designs needed to support firm conclusions (Blossom depression topic overview). A European psilocybin trial, PsyPal, is studying psychological distress in palliative care. This is a genuinely active research frontier — but "early" is the accurate label, and any provider presenting these uses as proven is overreaching.

What is being studied now

The pipeline is busier than at any prior point. For classic psilocybin, Compass Pathways has completed its Phase 3 program in treatment-resistant depression and, on its public timeline, is working toward a regulatory filing, with sites across several countries (Compass 26-week data). Cybin's CYB003 (a psilocin analog) is in its multinational PARADIGM Phase 3 program for major depression, with sites in the US and Europe and early pivotal results expected during 2026 (Cybin PARADIGM).

Worth noting alongside these, as a psilocybin-adjacent development: atai Life Sciences and Beckley Psytech reported positive Phase 2b topline data for BPL-003, an intranasal formulation of the short-acting psychedelic 5-MeO-DMT (mebufotenin) — not psilocybin, but the same broad class of serotonergic psychedelic-assisted therapy for treatment-resistant depression. The 193-patient study met its primary and key secondary endpoints, and the companies are planning Phase 3 with European sites (atai/Beckley Phase 2b; Psychiatric Times BPL-003). It is a signal that the psychedelic-therapy model, not psilocybin alone, is advancing.

You can follow current studies and their status on ClinicalTrials.gov, the EU Clinical Trials Information System and Blossom's trial database, and our own guide to joining a clinical trial in Europe explains what participation involves.

Safety and who should not take it

Psilocybin has a generally favourable physiological safety profile and low toxicity, and in supervised trials serious harms are uncommon. But it is not suitable for everyone, and the eligibility criteria used in research are the clearest guide to who is screened out. Trials of psilocybin and related psychedelics have typically excluded people with:

A personal or family history of psychosis or bipolar disorder (particularly bipolar I). This is the most consistent exclusion across classic-psychedelic studies, on the concern that a serotonergic psychedelic could precipitate or worsen a psychotic or manic episode in vulnerable individuals.
Significant or unstable cardiovascular disease, including uncontrolled hypertension, because psilocybin transiently raises heart rate and blood pressure.
Certain concurrent medications, notably some serotonergic drugs, which trial protocols manage carefully under medical supervision.
Pregnancy or breastfeeding, and in most protocols being under 18.

During a session, transient effects such as anxiety, nausea, a rise in blood pressure and challenging emotional experiences are common and are part of what the supervised setting is designed to hold. Beyond the session, a minority of people — mostly studied outside clinical trials, in uncontrolled settings — report prolonged difficulties. In one mixed-methods survey of 608 people reporting extended difficulties after psychedelic use, problems persisted for over a year in roughly a third of that self-selected sample (Evans et al., PLOS ONE 2023). That figure describes a group who already reported difficulties, not the general risk, and it largely reflects unsupervised use; but it is a real reason the supervised, screened, integration-supported model matters, and a reason to be cautious about non-clinical settings. None of this is a basis for alarm — it is a basis for careful screening by a qualified clinician.

Legal status and how access works in Europe

The default legal position across Europe is straightforward: psilocybin is a controlled substance, and supervised psilocybin therapy is lawful essentially only inside an authorised clinical trial. Trials are free, ethics-committee supervised and governed by participant rights, but screening is strict and enrolment is never guaranteed — our clinical trials guide explains phases, placebo and consent. Because psilocybin is investigational, it is generally not reimbursed by health systems outside research; see our reimbursement map for how coverage works across the continent.

Three national exceptions stand apart from the trial-only norm:

Czechia enacted a national framework making medical psilocybin legal from 1 January 2026, for defined serious conditions after authorised medicines have failed. Importantly, as of July 2026 the framework is live but delivery has not started and no waiting list exists — see our Czechia access guide.
Germany runs the EU's first psilocybin compassionate use program at two sites for treatment-resistant depression, with the initial listing period expiring in July 2026 and renewal not automatic — see our Germany access guide.
Switzerland allows a small number of authorised physicians to treat named patients with psilocybin (alongside LSD and MDMA) under a limited medical use program when standard treatments have failed — the only route of its kind in Europe, detailed in our Switzerland access guide.

To see what is actually available where you are, and whether you might fit a route, start with our eligibility check.

Frequently asked questions

Can I legally get psilocybin therapy in Europe today?

For most people, only by joining a clinical trial. Psilocybin is not an approved medicine in the EU, so supervised therapy outside research is not generally lawful. Three countries are exceptions with real limits: Czechia's new framework is legal but not yet delivering treatment, Germany's compassionate use program is tiny and time-limited, and Switzerland's limited medical use route runs through a small number of authorised physicians. Anyone offering psilocybin therapy commercially outside these routes is operating illegally.

Is psilocybin an approved treatment for depression?

Not yet, anywhere in Europe. The evidence in treatment-resistant depression is strong — two Phase 3 trials met their primary endpoints in 2025 and 2026 — but positive trial results are not the same as regulatory approval. A marketing application still has to be filed and reviewed before psilocybin could become an approved medicine.

How strong is the evidence, really?

It varies by condition. Treatment-resistant depression has the strongest evidence, now at Phase 3. Broader major depression is promising but rests on smaller studies, one of which did not beat an active comparator on its main measure. Uses in cancer-related distress and addictions are early. Being honest about these tiers matters more than any single headline.

Is psilocybin dangerous?

Under clinical supervision, serious harms are rare and its physiological toxicity is low. The main safeguards are screening — people with a history of psychosis or bipolar disorder, or significant heart disease, are generally excluded — and the supervised, supported setting. A minority of people, mostly using outside clinical settings, report prolonged psychological difficulties, which is one reason the controlled model exists.

Are the truffle retreats in the Netherlands the same thing?

No. Legal psilocybin truffle retreats operate under a quirk of Dutch law and are not medical treatment, not clinical trials, and not covered here as an evidence-based therapy. This page addresses the clinical and regulatory picture only.

Sources

This article is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. It does not provide guidance on obtaining, preparing or using any substance. The evidence and regulatory picture change quickly; always verify current details with official registries and a licensed clinician who knows your history. If you are in crisis, contact your local emergency number or a crisis line immediately.

This article awaits review by a licensed medical professional.

Psilocybin Therapy: What the Evidence Shows